Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of Bio017 for the treatment of Angelman Syndrome

Next Previous
X
Search
Trial Profile

Clinical trial of Bio017 for the treatment of Angelman Syndrome

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIO 017 (Primary)
  • Indications Angelman syndrome
  • Focus Adverse reactions
  • Sponsors Biom Therapeutics

    • Most Recent Events

    • 06 May 2021 Planned initiation date changed to 1 Oct 2021.
    • 28 Apr 2021 New trial record
    • 30 Mar 2021 According to a Biom Therapeutics media release, anticipates commencing clinical trials for BIO017 in Q4 of 2021, following submission of an Investigational New Drug (IND) application with the FDA in Q3 of this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top